Radiofrequency ablation for Barrett's oesophagus related neoplasia with the 360 Express catheter: initial experience from the United Kingdom and Ireland-preliminary results.
Barrett’s oesophagus
Early oesophageal neoplasia
Express device
Strictures
radio-frequency ablation
Journal
Surgical endoscopy
ISSN: 1432-2218
Titre abrégé: Surg Endosc
Pays: Germany
ID NLM: 8806653
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
received:
29
06
2020
accepted:
13
01
2021
pubmed:
7
2
2021
medline:
3
3
2022
entrez:
6
2
2021
Statut:
ppublish
Résumé
Radio-frequency ablation (RFA) for Barrett's oesophagus (BE)-related neoplasia is currently used after endoscopic resection of visible neoplasia. The HALO 360 balloon has been used to ablate long segment BE. The Barrx™ 360 Express RFA self-sizing catheter ('RFA Express') may potentially allow quicker ablation times and improved treatment outcomes. The aim of this paper is to present real world data on the use of the 360 Express Device. Centres in the UK and Ireland submitted cases where the RFA Express was used. The primary outcome was regression of BE at 3 months. Secondary outcomes were the rate of symptomatic stricture formation and resolution of intestinal metaplasia (CR-IM) and dysplasia (CR-D) at End of Treatment (EoT). 11 centres submitted 123 consecutive patients. 112 had a follow up endoscopy. The median age was 67 years (IQR 62-75). 3 dosimetries were used. The mean reduction in Circumferential (C) length was 78% ± 36 and mean reduction in Maximal length (M) was 55% ± 36. 17 patients (15%) developed strictures requiring dilation. There was a higher rate of stricture formation when the 12 J energy was used (p < 0.05). 47 patients had EoT biopsies, 40 (85%) had CR-D and 34(76%) had CR-IM. The RFA 360 Express catheter shows reduction in length of baseline BE at 3 months after index treatment, and eradication of intestinal metaplasia and dysplasia at 12 months similar to other studies with earlier devices. It appears that the symptomatic stricture rate is slightly higher than previous series with the HALO 360 catheter. This study was performed as part of the HALO registry and has been approved by the Research Ethics Committee - MREC Number 08/H0714/27 Local project reference 08/0104 Project ID 15,033 IRAS Number 54678 EudraCT 2009-015980-1. Registered on ISRCTN as below: ISRCTN93069556. https://doi.org/10.1186/ISRCTN93069556.
Sections du résumé
BACKGROUND
Radio-frequency ablation (RFA) for Barrett's oesophagus (BE)-related neoplasia is currently used after endoscopic resection of visible neoplasia. The HALO 360 balloon has been used to ablate long segment BE. The Barrx™ 360 Express RFA self-sizing catheter ('RFA Express') may potentially allow quicker ablation times and improved treatment outcomes. The aim of this paper is to present real world data on the use of the 360 Express Device.
METHODS
Centres in the UK and Ireland submitted cases where the RFA Express was used. The primary outcome was regression of BE at 3 months. Secondary outcomes were the rate of symptomatic stricture formation and resolution of intestinal metaplasia (CR-IM) and dysplasia (CR-D) at End of Treatment (EoT).
RESULTS
11 centres submitted 123 consecutive patients. 112 had a follow up endoscopy. The median age was 67 years (IQR 62-75). 3 dosimetries were used. The mean reduction in Circumferential (C) length was 78% ± 36 and mean reduction in Maximal length (M) was 55% ± 36. 17 patients (15%) developed strictures requiring dilation. There was a higher rate of stricture formation when the 12 J energy was used (p < 0.05). 47 patients had EoT biopsies, 40 (85%) had CR-D and 34(76%) had CR-IM.
CONCLUSIONS
The RFA 360 Express catheter shows reduction in length of baseline BE at 3 months after index treatment, and eradication of intestinal metaplasia and dysplasia at 12 months similar to other studies with earlier devices. It appears that the symptomatic stricture rate is slightly higher than previous series with the HALO 360 catheter. This study was performed as part of the HALO registry and has been approved by the Research Ethics Committee - MREC Number 08/H0714/27 Local project reference 08/0104 Project ID 15,033 IRAS Number 54678 EudraCT 2009-015980-1. Registered on ISRCTN as below: ISRCTN93069556. https://doi.org/10.1186/ISRCTN93069556.
Identifiants
pubmed: 33547491
doi: 10.1007/s00464-021-08325-0
pii: 10.1007/s00464-021-08325-0
pmc: PMC8741663
doi:
Banques de données
ISRCTN
['ISRCTN93069556']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
598-606Informations de copyright
© 2021. The Author(s).
Références
Scand J Gastroenterol. 2018 May;53(5):527-532
pubmed: 29161901
United European Gastroenterol J. 2018 Aug;6(7):990-999
pubmed: 30228886
Am J Gastroenterol. 2016 Jan;111(1):30-50; quiz 51
pubmed: 26526079
Gut. 2015 Aug;64(8):1192-9
pubmed: 25539672
Gut. 2014 Jan;63(1):7-42
pubmed: 24165758
Endoscopy. 2008 May;40(5):370-9
pubmed: 18494132
Gastrointest Endosc. 2000 Sep;52(3):328-32
pubmed: 10968845
Minerva Gastroenterol Dietol. 2003 Mar;49(1):63-70
pubmed: 16481972
Clin Gastroenterol Hepatol. 2013 May;11(5):491-98.e1
pubmed: 23267867
Gastrointest Endosc. 2007 Feb;65(2):185-95
pubmed: 17258973
Endoscopy. 2012 Dec;44(12):1105-13
pubmed: 22968641
Gastrointest Endosc. 2019 Sep;90(3):415-423
pubmed: 31108093
Gut. 2016 Apr;65(4):555-62
pubmed: 25731874
Endoscopy. 2017 Feb;49(2):191-198
pubmed: 28122386
JAMA. 2014 Mar 26;311(12):1209-17
pubmed: 24668102
N Engl J Med. 2009 May 28;360(22):2277-88
pubmed: 19474425
Gut. 2008 Sep;57(9):1200-6
pubmed: 18460553
Gastrointest Endosc. 2004 Dec;60(6):1002-10
pubmed: 15605025
Gastroenterology. 2013 Jul;145(1):87-95
pubmed: 23542069
Gastrointest Endosc. 2018 Nov;88(5):795-803.e2
pubmed: 29928869